GSK plc reported positive Phase III trial results on March 16, 2024, showing dostarlimab plus chemotherapy significantly improves overall survival in patients with advanced endometrial cancer, with a 31% reduction in risk of death and a median OS increase of 16.4 months over chemotherapy alone.